Cabazitaxel

Generic Name: Cabazitaxel

Brand Names: Jevtana, Cabazitaxel Accord

Drug Type: Small Molecule

Chemical Formula: C_₄₅H_₅₇NO_₁₄

CAS Number: 183133-96-2

Unique Ingredient Identifier: 51F690397J

Background: Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like paclitaxel and docetaxel.

Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.

Indication: 用于治疗转移性去势抵抗性前列腺癌患者。

Associated Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Trials

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent

Phase 4

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Drug: cabazitaxel XRP6258
Drug: enzalutamide
Drug: prednisone
Drug: abiraterone acetate

First Posted Date: 2015-06-30

Last Posted Date: 2022-05-27

Lead Sponsor: Sanofi

Target Recruit Count: 255

Registration Number: NCT02485691

Locations: 🇧🇪
Investigational Site Number 056007, Brussels, Belgium
🇧🇪
Investigational Site Number 056005, Leuven, Belgium
🇫🇷
Investigational Site Number 250010, Clermont Ferrand, France

and more 62 locations

Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

Phase 2

Terminated

Conditions: Testicular Cancer

Interventions: Drug: cabazitaxel

First Posted Date: 2015-06-23

Last Posted Date: 2024-02-02

Lead Sponsor: University Hospital, Akershus

Target Recruit Count: 14

Registration Number: NCT02478502

Locations: 🇮🇹
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T), Meldola, Italy
🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇸🇪
University Hospital of Uppsala, Department of Oncology, Uppsala, Sweden

and more 1 locations

Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: CABAZITAXEL XRP6258
Drug: PEG-G-CSF
Drug: Prednisolone
Drug: Dexchlorpheniramine or Diphenhydramine
Drug: Ranitidine
Drug: Metoclopramide, Granisetron, or Ondansetron
Drug: Dexamethasone

First Posted Date: 2015-05-12

Last Posted Date: 2017-01-24

Lead Sponsor: Sanofi

Target Recruit Count: 21

Registration Number: NCT02441894

Locations: 🇯🇵
Investigational Site Number 392008, Kita-gun, Japan
🇯🇵
Investigational Site Number 392001, Shinjuku-ku, Tokyo, Japan
🇯🇵
Investigational Site Number 392004, Chuo-ku, Chiba, Japan

and more 5 locations

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

Phase 2

Terminated

Conditions: Prostate Cancer Metastatic

Interventions: Drug: Ezalutamide
Drug: Cabazitaxel XRP6258
Drug: Prednisone
Drug: Abiraterone acetate

First Posted Date: 2015-03-04

Last Posted Date: 2019-06-21

Lead Sponsor: Sanofi

Target Recruit Count: 8

Registration Number: NCT02379390

Locations: 🇨🇦
Investigational Site Number 124005, Hamilton, Canada
🇨🇦
Investigational Site Number 124002, Montreal, Canada
🇨🇦
Investigational Site Number 124009, Quebec, Canada

and more 21 locations

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

Phase 2

Conditions: Metastatic Castration-Resistant Prostatic Cancer

Interventions: Drug: cabazitaxel
Drug: Abiraterone
Drug: Enzalutamide 160mg daily (oral)

First Posted Date: 2014-10-02

Last Posted Date: 2017-12-06

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 120

Registration Number: NCT02254785

Locations: 🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇨🇦
Durham Regional Cancer Centre (Lakeridge Health), Oshawa, Ontario, Canada

and more 12 locations

Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone acetate 1000 mg po daily
Drug: prednisone 5 mg po BID
Drug: Cabazitaxel 25 mg/m2 IV

First Posted Date: 2014-08-18

Last Posted Date: 2024-12-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 81

Registration Number: NCT02218606

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Weill Cornell Medical Center, New York, New York, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

and more 1 locations

Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Other: Best Supportive Care
Drug: Cabazitaxel

First Posted Date: 2014-07-30

Last Posted Date: 2014-07-30

Lead Sponsor: Hospital Clinico Universitario de Santiago

Target Recruit Count: 38

Registration Number: NCT02204332

Locations: 🇪🇸
Hospital General de Valencia, Valencia, Spain
🇪🇸
Hospital Clinico de Santiago, Santiago de Compostela, Spain
🇪🇸
Hospital Arnau de Vilanova, Lérida, Spain

and more 5 locations